RxDoctor Payments Data

Jonathan Lee, MD

Internal Medicine · Jamaica Plain, MANPI 1003917626

Payments from drug & device makers

$9,300in general payments, 2019–2025

Across 508 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Amgen$906
  • Lilly USA, LLC$688
  • Novo Nordisk$635
  • Pfizer$615
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$9,283100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,300 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$60,637
Medicare patients
321
Services billed
1,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide24$43,051
JardianceEmpagliflozin26$33,794
EliquisApixaban32$30,965
FarxigaDapagliflozin Propanediol20$24,365
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$14,947
JanuviaSitagliptin Phosphate11$7,114
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$4,356
Wixela InhubFluticasone Propion/Salmeterol40$3,276
Atorvastatin Calcium163$2,436
OxycontinOxycodone Hcl11$1,849
Metoprolol Succinate73$1,727
Chlorthalidone45$1,436
Albuterol Sulfate HfaAlbuterol Sulfate50$1,251
Rosuvastatin Calcium33$1,217
Ramipril56$1,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$688$43,05124 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,743$39,31234 claims
Boehringer IngelheimJardiance$239$33,79426 claims
PfizerEliquis$615$30,96532 claims
MerckJanuvia$180$7,11411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Jamaica Plain

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →